TScan Therapeutics, Inc.
TScan Therapeutics, Inc.
Your view on TCRX
Overview
What the company does, where it operates, and who runs it.
About TScan Therapeutics, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Gavin MacBeath
- Headquarters
- 830 Winter Street, Waltham, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Gavin MacBeath
- Headquarters
- 830 Winter Street, Waltham, MA, US
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer.
It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors.
The company is also developing vaccines for infectious diseases, such as SARS-CoV-2.
It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for TScan Therapeutics, Inc., and the rating behind it. TCRX last traded at $0.32; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for TScan Therapeutics, Inc.. Starting points for TScan Therapeutics, Inc.: EPS -$0.91, beta 1.07 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for TScan Therapeutics, Inc.. TScan Therapeutics, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for TScan Therapeutics, Inc.. Trailing twelve-month EPS for TScan Therapeutics, Inc. stands at -$0.91. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for TScan Therapeutics, Inc.. TScan Therapeutics, Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
TScan Therapeutics, Inc. valued side by side against its closest peers. TScan Therapeutics, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold TScan Therapeutics, Inc., and how their positions are changing. At a $19.6M market value, institutional positions materially move TScan Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by TScan Therapeutics, Inc. executives and directors. Shares of TScan Therapeutics, Inc. have traded between $0.96 and $4.94 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming TScan Therapeutics, Inc.. TScan Therapeutics, Inc. is a $19.6M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming TScan Therapeutics, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for TScan Therapeutics, Inc.. Coverage tracks TScan Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.